Minimal residual disease, overall response rate, complete response rate, and stringent complete response may be useful as surrogate end points to estimate progression-free survival (PFS) benefit for patients with newly diagnosed multiple myeloma.
In patients with newly diagnosed multiple myeloma (NDMM), progression-free survival (PFS) was significantly associated with overall response rate (ORR), complete response (CR), stringent CR (sCR), and minimal residual disease (MRD), indicating that they may be used as surrogate end points to estimate PFS benefit, according to a poster presented at the European Hematology Association 2021 Virtual Congress.
While overall survival is the gold standard of clinical end points, it requires a larger sample size and longer follow-up, and PFS is more commonly used as the primary survival end point in NDMM trials, the authors explained. “Validation of short-term surrogate endpoints for PFS that could be measured earlier is therefore of interest and appropriate in NDMM,” they wrote.
They conducted a systematic literature review using MEDLINE, EMBASE, and Cochrane databases, as well as a review of real-world evidence studies. Pearson’s correlation weighted by the sample size in each study arm was used to estimate correlations between PFS and ORR, CR, sCR, and MRD.
Seventy-five randomized controlled trials with 101 arms reported median PFS and were included in the review. They found:
The review of real-world evidence included 49 studies with 10,082 patients. Thirty-seven studies were retrospective and 30 studies were done at a single center. Only 20 of the studies investigated correlations of OS/PFS with MRD/sCR. The studies showed:
The findings of both the literature review of randomized controlled trials and of real-world evidence studies support other evidence that MRD negativity is a “viable surrogate for PFS” in multiple myeloma, the authors wrote.
“Being able to predict survival outcomes through response end points available earlier in a trial may help to inform decisions on, and accelerate access to, novel therapeutics and drug combinations in NDMM,” they concluded.
Reference
Daniele P, Mamolo C, Cappelleri JC, et al. Overall, complete, and stringent complete response rates and minimal residual disease as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. Presented at: EHA2021 Virtual Congress; June 9-17, 2021. Poster EP1025.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen